Skip to content
Clinical Trials – home

Dermoklinika - Centrum Medyczne s.c. M. Kierstan J. Narbutt A. Lesiak

Verified siteinfo

Poland Aleja T. Kosciuszki 93, 90-436 Lodz, Poland

  • 8 trials recruiting
  • Psoriasis · Dermatitis atopic · Hidradenitis
  • Adults and children

About Specializations

Dermoklinika - Centrum Medyczne s.c. M. Kierstan J. Narbutt A. Lesiak in Lodz, Poland specialises in clinical trials of conditions such as Psoriasis, Dermatitis atopic, Hidradenitis, Alopecia areata, and other specialisations. This site conducts important research.

Main research areas of the site

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

The centre conducts research on rare genetic skin disorders, aiming to evaluate the safety and effectiveness of novel topical and systemic treatments for conditions that appear at birth or in early childhood.

  • Gorlin Syndrome
  • Generalized Epidermolysis Bullosa Simplex
  • Other congenital skin abnormalities

With 63 trials underway and a dedicated team of two investigators, Dermoklinika – Centrum Medyczne is building a knowledge base that could improve outcomes for patients with these challenging diseases.

Immune System Diseases

Studies focus on autoimmune skin conditions such as lupus erythematosus and chronic urticaria, seeking new therapeutic options to reduce disease activity and enhance quality of life.

  • Cutaneous Lupus Erythematosus
  • Chronic Spontaneous Urticaria
  • Chronic Urticaria

The trials aim to identify safer, more effective treatments for patients whose immune systems target their own skin.

Skin and Connective Tissue Diseases

A broad portfolio addresses common inflammatory dermatoses, including psoriasis, atopic dermatitis, hidradenitis suppurativa, vitiligo, and alopecia areata, with the goal of testing innovative therapies and improving disease management.

  • Plaque Psoriasis
  • Moderate-to-Severe Atopic Dermatitis
  • Hidradenitis Suppurativa
  • Nonsegmental Vitiligo
  • Alopecia Areata

Long‑term safety and efficacy are evaluated across adult and pediatric populations, reflecting the centre’s commitment to comprehensive skin health.

Immune System Phenomena

Research explores the underlying immunological patterns that drive skin inflammation, using biomarker analysis to better understand disease pathways.

  • Cytokine profiling in psoriasis
  • T‑cell activity in vitiligo
  • Immune cell phenotypes in atopic dermatitis

These investigations support the development of precision medicines that target specific immune signatures.

Immune System Processes

The site evaluates key signaling cascades such as JAK‑STAT and IL‑17 pathways, testing agents that modulate these processes to alleviate skin disease.

  • JAK inhibition in atopic dermatitis
  • IL‑17 blockade in psoriasis
  • BTK inhibition in chronic urticaria

By focusing on these molecular mechanisms, the trials aim to bring targeted therapies to patients with refractory conditions.

General Dermatology Research

Additional studies cover a wide range of dermatologic conditions, including pediatric and adult forms of plaque psoriasis, prurigo nodularis, and palmoplantar pustulosis, reflecting a versatile research agenda.

  • Pediatric plaque psoriasis
  • Adult moderate‑to‑severe plaque psoriasis
  • Prurigo Nodularis
  • Palmoplantar pustulosis

Located at Al. Kosciuszki 93 in Łódź, Poland, Dermoklinika – Centrum Medyczne provides a platform for diverse clinical investigations across Europe.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Aleja T. Kosciuszki 9390-436 LodzPoland
Recruiting now
8 trials
Conditions studied
10
Partner status
Verified site

More sites in LodzPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

31 clinical trials

Vitiligo+2

Recruiting

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Psoriasis

Recruiting

A study to evaluate the effectiveness and safety of zasocitinib in children and adolescents with moderate-to-severe plaque psoriasis

Investigational
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

A study to evaluate the long-term safety and effectiveness of afimkibart in patients with atopic dermatitis who took part in previous afimkibart studies

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Alopecia areata

Recruiting

Long-term safety and effectiveness study of ritlecitinib in children with severe alopecia areata who completed previous trials B7981027 or B7981031

Investigational
Countries:PolandPoland
  • Participants:0–17 years
  • Sponsor:Pfizer Inc.

Study of abrocitinib oral suspension for children aged 2 years and older with moderate to severe atopic dermatitis to evaluate long-term safety and effectiveness

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Abrocitinib
  • Sponsor:Pfizer Inc.

Effectiveness and Safety of Abrocitinib in Children 6 to Under 12 Years with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Abrocitinib
  • Sponsor:Pfizer Inc.

Study on Diacerein 1% Ointment for Treating Generalized Epidermolysis Bullosa Simplex in Patients Aged 6 Months and Older

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Diacerein
  • Sponsor:Twi Biotechnology Inc.

Psoriasis

Recruiting

Study on Tildrakizumab and Etanercept for Children Aged 6 to 17 with Moderate to Severe Plaque Psoriasis

Registered drug
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Etanercept
  • Sponsor:Sun Pharmaceutical Industries Limited

Dermatitis atopic

Not yet recruiting

Study to evaluate ATI-045 injection compared to placebo in adults with moderate to severe atopic dermatitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:HUMANISED IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST THYMIC STROMAL LYMPHOPOIETIN
  • Sponsor:Aclaris Therapeutics Inc.

Hidradenitis

Not recruiting

Evaluation of CIT-013 at two dose levels compared to placebo for treating moderate to severe Hidradenitis Suppurativa

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:CIT-013
  • Sponsor:Citryll B.V.

Psoriasis

Not recruiting

Comparison of zasocitinib and deucravacitinib in adults with moderate to severe plaque psoriasis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Takeda Development Center Americas Inc.

Psoriasis

Not recruiting

Study of TAK-279 and apremilast for adults with moderate to severe plaque psoriasis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Takeda Development Center Americas Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.